MA31029B1 - Formes cristallines de glyt1 - Google Patents
Formes cristallines de glyt1Info
- Publication number
- MA31029B1 MA31029B1 MA32049A MA32049A MA31029B1 MA 31029 B1 MA31029 B1 MA 31029B1 MA 32049 A MA32049 A MA 32049A MA 32049 A MA32049 A MA 32049A MA 31029 B1 MA31029 B1 MA 31029B1
- Authority
- MA
- Morocco
- Prior art keywords
- crystalline forms
- preparation
- glyt1
- rifluoro
- psychoses
- Prior art date
Links
- 102100022622 Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase Human genes 0.000 title 1
- 101000972916 Homo sapiens Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase Proteins 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- -1 3-FLUORO-5-TRIFLUOROMETHYL-PYRIDIN-2-YL Chemical class 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 230000019771 cognition Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06127269 | 2006-12-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA31029B1 true MA31029B1 (fr) | 2009-12-01 |
Family
ID=38988312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA32049A MA31029B1 (fr) | 2006-12-28 | 2009-06-29 | Formes cristallines de glyt1 |
Country Status (33)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0720829B8 (pt) | 2006-12-28 | 2021-05-25 | Hoffmann La Roche | formas cristalinas de glyt1, seu método de preparação, seu uso e composição farmacêutica que as compreende |
| WO2010099323A1 (en) | 2009-02-26 | 2010-09-02 | Thar Pharmaceuticals, Inc. | Crystalization of pharmaceutical compounds |
| KR101196354B1 (ko) * | 2010-09-03 | 2012-11-01 | 서유헌 | 퇴행성 신경계 뇌 질환의 예방 또는 치료용 약학 조성물 |
| US9328101B2 (en) * | 2012-05-25 | 2016-05-03 | Basf Se | Crystalline form B of 1,5-dimethyl-6-thioxo-3-(2,2,7-trifluoro-3-oxo-4-(prop-2-ynyl)-3,4-dihydro-2H-benzo[B][1,4]oxazin-6-yl)-1,3,5-triazinane-2,4-dione |
| US8927412B1 (en) * | 2013-08-01 | 2015-01-06 | Taiwan Semiconductor Manufacturing Company, Ltd. | Multi-chip package and method of formation |
| MX354615B (es) * | 2013-10-02 | 2018-03-08 | Centro De Investig Y De Estudios Avanzados Del I P N | Uso del propilparabeno comoagente neuroprotector en el daño neuronal inducido por status epilepticus. |
| KR20220125326A (ko) | 2020-01-09 | 2022-09-14 | 디스크 메디슨, 인크. | 적혈구형성 프로토포르피린증, x-연계된 프로토포르피린증, 또는 선천성 적혈구 조혈포르피린증을 글리신 운반 억제제로 치료하는 방법 |
| WO2022014395A1 (ja) * | 2020-07-13 | 2022-01-20 | 日本碍子株式会社 | 精製方法 |
| CN117979967A (zh) * | 2021-05-14 | 2024-05-03 | 迪斯克医药公司 | 用甘氨酸转运蛋白抑制剂治疗红细胞生成性原卟啉病、x连锁原卟啉病或先天性红细胞生成性卟啉病的方法 |
| EP4347023A4 (en) * | 2021-05-27 | 2025-04-16 | Disc Medicine, Inc. | Method for treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with a solid form of bitopertin |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL154370A0 (en) | 2003-02-10 | 2003-09-17 | Chemagis Ltd | Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same |
| NZ544820A (en) * | 2003-08-11 | 2009-02-28 | Hoffmann La Roche | Piperazine with or-substituted phenyl group and their use as GlyT1 inhibitors |
| BRPI0720829B8 (pt) | 2006-12-28 | 2021-05-25 | Hoffmann La Roche | formas cristalinas de glyt1, seu método de preparação, seu uso e composição farmacêutica que as compreende |
-
2007
- 2007-12-18 BR BRPI0720829A patent/BRPI0720829B8/pt active IP Right Grant
- 2007-12-18 JP JP2009543441A patent/JP4799666B2/ja active Active
- 2007-12-18 ES ES07857734.3T patent/ES2535040T3/es active Active
- 2007-12-18 KR KR1020097015643A patent/KR101130146B1/ko active Active
- 2007-12-18 RS RS20150229A patent/RS53910B1/sr unknown
- 2007-12-18 UA UAA200907731A patent/UA100232C2/uk unknown
- 2007-12-18 PT PT78577343T patent/PT2114405E/pt unknown
- 2007-12-18 DK DK07857734T patent/DK2114405T3/en active
- 2007-12-18 EP EP07857734.3A patent/EP2114405B1/en active Active
- 2007-12-18 MX MX2009006859A patent/MX2009006859A/es active IP Right Grant
- 2007-12-18 CA CA002673667A patent/CA2673667A1/en not_active Abandoned
- 2007-12-18 MY MYPI20092584A patent/MY188367A/en unknown
- 2007-12-18 WO PCT/EP2007/064104 patent/WO2008080821A1/en not_active Ceased
- 2007-12-18 HU HUE07857734A patent/HUE025032T2/en unknown
- 2007-12-18 RU RU2009124113/04A patent/RU2463295C2/ru active
- 2007-12-18 CN CNA2007800479512A patent/CN101573114A/zh active Pending
- 2007-12-18 SI SI200731644T patent/SI2114405T1/sl unknown
- 2007-12-18 PL PL07857734T patent/PL2114405T3/pl unknown
- 2007-12-18 AU AU2007341356A patent/AU2007341356B2/en active Active
- 2007-12-18 NZ NZ577502A patent/NZ577502A/en unknown
- 2007-12-18 HR HRP20150573TT patent/HRP20150573T1/hr unknown
- 2007-12-19 US US12/002,997 patent/US20080214561A1/en not_active Abandoned
- 2007-12-25 TW TW096150002A patent/TWI388552B/zh active
- 2007-12-27 CL CL200703830A patent/CL2007003830A1/es unknown
- 2007-12-27 AR ARP070105913A patent/AR064545A1/es not_active Application Discontinuation
-
2008
- 2008-01-02 PE PE2008000055A patent/PE20081556A1/es not_active Application Discontinuation
-
2009
- 2009-06-08 CR CR10846A patent/CR10846A/es unknown
- 2009-06-11 CO CO09061117A patent/CO6190613A2/es not_active Application Discontinuation
- 2009-06-19 NO NO20092358A patent/NO342150B1/no unknown
- 2009-06-24 ZA ZA200904423A patent/ZA200904423B/xx unknown
- 2009-06-26 EC EC2009009471A patent/ECSP099471A/es unknown
- 2009-06-29 MA MA32049A patent/MA31029B1/fr unknown
-
2010
- 2010-07-22 US US12/841,195 patent/US8039473B2/en not_active Expired - Fee Related
-
2011
- 2011-07-22 US US13/188,486 patent/US20110295007A1/en not_active Abandoned
-
2012
- 2012-06-13 US US13/495,093 patent/US20120309969A1/en not_active Abandoned
-
2013
- 2013-03-13 US US13/798,358 patent/US20130197225A1/en not_active Abandoned
-
2015
- 2015-05-20 CY CY20151100451T patent/CY1116350T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA27482A1 (fr) | Piperazines, (1,4) diazepines, et 2,5-diazabicyclo (2.2.1) heptanes substitues en tant qu'antagonistes de l'histamine h1 et/ou h3 ou antagonistes inverses de l'histamine h3 | |
| TN2009000471A1 (fr) | Composes amino-heterocycliques | |
| MA27675A1 (fr) | Derives de piperazine et leur utilisation dans le traitement de maladies neurologiques et psychiatriques | |
| UA100232C2 (uk) | Кристалічні форми інгібітора glyt1 | |
| MA27995A1 (fr) | Piperazine avec groupe phenyle substitue de type or et leur utilisation comme inhibiteurs de glyt1 | |
| TW200502221A (en) | Novel lactams and uses thereof | |
| CA2433585A1 (en) | Pharmaceutical compositions containing donepezil hydrochloride | |
| TNSN05104A1 (fr) | Derives de thiazole pour le traitement de troubles neurodegeneratifs | |
| UA83899C2 (uk) | Сполуки імідазолу для лікування нейродегенеративних розладів | |
| MA29871B1 (fr) | Composition pharmaceutique concue pour ameliorer la fonction cognitive | |
| MA31521B1 (fr) | Dérivés de 2,3-dihydrobenzo[1,4] dioxin-2-ylméthyle utilisés en tant qu'antagonistes des alpha2c pour traiter des maladies des systèmes nerveux périphérique et central | |
| MA27775A1 (fr) | Composes organiques | |
| CA2501799A1 (en) | Pyrazole compounds for treatment of neurodegenerative disorders | |
| WO2004085433A3 (en) | Positive allosteric modulators of the nicotinic acetylcholine receptor | |
| WO2003070731A3 (en) | Azabicyclic compounds for the treatment of disease | |
| MesserJr | Cholinergic agonists and the treatment of Alzheimer's disease | |
| NO20071967L (no) | Imidazo-benzodiazepinderivater | |
| WO2006040451A2 (fr) | Nouveaux derives de 9h-pyrido (2, 3-b) indole en tant qu'inhibiteurs de cdk et gsk3 , leur procede de preparation, ainsi que les compositions pharmaceutiques contenant de tels composes | |
| MXPA04003298A (es) | Compuestos de piperidina como antagonistas muscarinicos. | |
| WO2005003103A3 (en) | 2, 4, 6-tri-substituted 6-membered heterocycles and their use in the treatment of neurodegenerative diseases | |
| JP7157471B2 (ja) | （ｒ）－ジミラセタム（１）と（ｓ）－ジミラセタム（２）を非ラセミ比で含む相乗的組成物 | |
| EP2077719A4 (en) | PIPERIDINE AND PYRROLIDIN BETA SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER DISEASE | |
| TNSN08138A1 (fr) | Derives d'imidazole pour le traitement de troubles neurologiques | |
| EP1972342A4 (en) | PHARMACEUTICAL TREATED SALT (VI) COMPOSITIONS FOR THE TREATMENT OF NEURODEEGENERATIVE DISORDERS, IN PARTICULAR ALZHEIMER DISEASE AND SCHIZOPHRENIA | |
| Gao et al. | Synthesis and biological evaluation of ranitidine analogs as multiple-target-directed cognitive enhancers for the treatment of Alzheimer’s disease |